Novo Nordisk Toughens Long-Term Financial Targets As 2010 Sales Grew By 13%, Profits By 16%
This article was originally published in The Pink Sheet Daily
Executive Summary
Victoza and its modern insulins franchise drive 2010 revenues growth at Danish diabetes specialist Novo Nordisk.
You may also be interested in...
More Insulin Innovation To Come, Says Novo CEO Sorensen
Market-leader Novo is confident it can continue to innovate in insulin – and command premium prices
Lixisenatide Gains Evidence Of A Weight Loss Benefit
Sanofi/Zealand's GLP-1 agonist lixisenatide continues to show promise in the latest GetGoal results, this time in type 2 diabetics inadequately controlled on sulfonylureas.
Lixisenatide Gains Evidence Of A Weight Loss Benefit
Sanofi/Zealand's GLP-1 agonist lixisenatide continues to show promise in the latest GetGoal results, this time in type 2 diabetics inadequately controlled on sulfonylureas.